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Abstract
Lung cancer causes more deaths, worldwide, than any other cancer. Several histologic subtypes exist. Currently,
there is a dearth of targeted therapies for treating one of the main subtypes: squamous cell carcinoma (SCC). As for
many cancers, lung SCC karyotypes are often highly anomalous owing to large somatic structural variants, some of
which are seen repeatedly in lung SCC, indicating a potential causal association for genes therein. We chose to
characterize a lung SCC genome to unprecedented detail and integrate our findings with the concurrently charac-
terized transcriptome. We aimed to ascertain how somatic structural changes affected gene expression within the
cell in ways that could confer a pathogenic phenotype. We sequenced the genomes of a lung SCC cell line (LUDLU-1)
and its matched lymphocyte cell line (AGLCL) to more than 50× coverage. We also sequenced the transcriptomes
of LUDLU-1 and a normal bronchial epithelium cell line (LIMM-NBE1), resulting in more than 600 million aligned reads
per sample, including both coding and non-coding RNA (ncRNA), in a strand-directional manner. We also captured
small RNA (<30 bp). We discovered significant, but weak, correlations between copy number and expression for
protein-coding genes, antisense transcripts, long intergenic ncRNA, and microRNA (miRNA). We found that miRNA
undergo the largest change in overall expression pattern between the normal bronchial epithelium and the tumor
cell line. We found evidence of transcription across the novel genomic sequence created from six somatic structural
variants. For each part of our integrated analysis, we highlight candidate genes that have undergone the largest
expression changes.
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Introduction
In the United Kingdom, there is a death from lung cancer every
15 minutes. This is due to the high prevalence of the disease, late
stage at presentation, and inadequate treatment options. As for other
tumor types, molecular genetic analysis has identified specific drug
targets that allow more individualized treatments, but in lung cancer,
only for the adenocarcinoma histologic subtype, this has been trans-
lated into novel therapies [1–5]. The squamous cell carcinoma (SCC)
subtype, although reducing in prevalence in developed countries [6],
predominates in developing countries such as India and Indonesia
and is predicted to be responsible for millions of deaths as the smok-
ing epidemic sweeps through Southeast Asia. Although surgery is the
preferred option for early stage disease, many patients present with
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disseminated disease or with comorbidities that preclude surgery.
Thus, the discovery of new drugs is urgent, requiring a search for effec-
tive drug targets; following success in other cancers, identification of
tumor-specific genomic abnormalities is expected to be a valuable
approach. Accordingly, lung SCC was named as one of the three
tumors to be analyzed by high-throughput methods in the pilot study
of The Cancer Genome Atlas (TCGA). The traditional approach to
the task of identifying genomic drivers of tumor development and
progression has involved comparing large numbers of tumor samples
looking for common features, an effective strategy when the objective
is to identify tumor markers. However, comparing multiple genomes,
while obviously an important starting point, has revealed a dearth of
significantly mutated genes that could constitute potential drug targets
for specific cancer types [7]. It is likely that there is a requirement for a
more functional understanding of the malignant phenotype based on
recognition of the multiplicity of affected genes and signal transduction
pathways acting in concert.
Application of high-coverage, high-throughput sequencing to the
whole genomes of single samples of small cell and adenocarcinoma,
the other main lung cancer histotypes, was able to reveal insights
into disease etiology and selective pressures within the tumor micro-
environment [8,9]. Here, we have questioned whether the same
approach can yield further insight into the biology of, and reveal can-
didate carcinogenic mechanisms for, lung SCC by next-generation
sequencing of an appropriate tumor cell line (LUDLU-1) and a
matched lymphocyte cell line (AGLCL). However, to further under-
stand the cellular consequences of somatic events and allow us to
prioritize them functionally, we integrated our genomic data with
that of the transcriptome by also undertaking high-coverage RNAseq
of both LUDLU-1 and a normal bronchial epithelial cell line (LIMM-
NBE1). We captured coding, non-coding, and small transcripts in a
strand-directional manner, making ours the first study, to our knowl-
edge, to provide an integrated whole-genome and whole-transcriptome
analysis to this level of transcriptional detail. Our aim was not only to
catalogue genomic abnormalities but also to determine if they are func-
tionally active by revealing the consequences for gene expression both
for coding and non-coding genes and also to consider how their com-
bined effect could contribute to malignancy in this tumor specimen.
We provide general results from our genome-wide analysis as well as a
list of genes and events that were highlighted by our integrated approach.
Materials and Methods
Cell Lines
LUDLU-1 is a cell line derived from a lung SCC, and AGLCL is its
matching EBV-transformed lymphoblast cell line [10]. Both were cul-
tured using standard cell culture techniques. The LUDLU-1 cell line
was shown by immunohistochemistry, after being formalin fixed and
paraffin-embedded, to be positive for P63 and negative for TTF-1,
confirming it to be a lung SCC (results not shown). LIMM-NBE1 is
a transformed bronchial epithelial cell line established for this study.
Briefly, a primary culture derived from normal lung tissue was exposed
to a TERT gene lentiviral vector after passage 5. Its epithelial origin was
confirmed using antibodies to cytokeratin (results not shown). The cells
were cultured in serum-free defined medium using standard techniques
and DNA/RNA was prepared after passage 39 from cells harvested in
the exponential growth phase. Written consent was obtained from the
patient and ethics approval was given by the Leeds West Research
Ethics Committee (07/H13071/146).
Multicolor fluorescence in situ hybridization
Chromosomes were prepared from LUDLU-1 cell cultures follow-
ing standard procedures and labeled using the Metasystems 24XCyte
mFISH probe kit together with a 4′,6-diamino-2-phenylindole counter-
stain. Images were recorded andmerged using a Zeiss Axioskopmicroscope
with Smart Capture 3.1.0 and pseudocolored and identified using Smart
Type software (both Digital Scientific Ltd, Cambridge, United Kingdom).
DNA/RNA Extraction
DNA and total RNA were co-extracted from cell lines using TRIzol
Reagent (Life Technologies, Paisley, United Kingdom), following the
manufacturer’s instructions. To remove phenol contamination, total
RNA was repurified using the RNeasy Kit (Qiagen, Crawley, United
Kingdom). Quality control consisted of quantification using Qubit
Assay Kits and the Qubit f luorometer (Life Technologies) and mea-
surement of DNA/RNA integrity using gel electrophoresis and the
Agilent Bioanalyzer (Agilent Technologies, Stockport, United Kingdom).
Ribosomal RNA was removed from total RNA, by LGC Genomics,
using Ribo-Zero Kit (Epicentre Biotechnologies, Madison, WI).
Sequencing
DNA was sequenced by Complete Genomics for LUDLU-1 and
AGLCL as described in Drmanac et al. [11]. LIMM-NBE1 DNA was
sequenced to low coverage (0.06×), for the purposes of copy number
estimation, on an Illumina GAII according to Wood et al. [12].
Two RNAseq libraries were prepared using Illumina protocols that
were optimized, in-house, by LGC Genomics: one strand-specific
and one small RNA library. Single-end reads (50 bp) were sequenced
using an Illumina HiSeq 2000.
Sequencing Read Archive accession numbers are ERP001771 (high-
coverage LUDLU-1 and AGLCL DNA sequencing), ERP001814
(low-coverage LIMM-NBE1 DNA sequencing), and ERP001465
(LUDLU-1 and LIMM-NBE1 RNA sequencing).
Alignment
All sequenced reads were aligned to National Center for Biotech-
nology Information human genome reference build 37, except for the
small RNA reads, which were aligned to build 36 known microRNA
(miRNA) using miRanalyzer [13]. DNA reads were aligned as part of
the Complete Genomic pipeline [11]. Adaptor sequence was removed
from RNA reads, which were then trimmed from the 3′ end to
ensure an average Phred-scaled quality of 20. Strand-specific RNA
reads >19 bp were aligned using Tophat [14], with a maximum of
4% mismatches and segment lengths set to half the read length for
reads >33 bp. Reads that aligned to more than five genomic loca-
tions were discarded. Strand-specific RNA reads <20 bp were aligned
to National Center for Biotechnology Information human reference
genome build 36 using miRanalyzer [13].
Mutation Detection
Structural variants were extracted from the appropriate Junctions files,
supplied as standard with Complete Genomics sequencing data [15].
Mutation Validation
Sixty somatic structural variants were selected for validation by poly-
merase chain reaction and Sanger sequencing, based on their predicted
ability to interfere with the transcription of genes. Primer design failed
for three, but of the 57 that we were able to successfully investigate,
there were two false positives (germ line) and 55 true positives.
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Copy Number Data
For LUDLU-1 and AGLCL, we used an adapted version of the
script bam2windows.pl from CNAnorm [16] to count reads from
the raw data provided by Complete Genomics (the mapping_* tsv.
bz2 files) across 50-kb windows. We excluded reads not mapping
uniquely, those with quality score < 5, and those where the two reads
in a pair are mapping on different chromosomes, or more than 1000 bp
apart. Other parameters were left as default.
Copy number analysis for LIMM-NBE1 was performed using
CNAnorm. A control sample was made using data from a pool of
20 British individuals downloaded from the 1000 genomes project
(PMID 20981092). Aligned LIMM-NBE1 reads were split into win-
dows of 300 kb, averaging 200 reads per window. CNAnorm was used
to estimate copy number with normalization method set to “closest.”
Expression Analysis
Gene annotation files, including assignment of transcript subtype,
were downloaded from Ensembl 60 [17] and transcript records
merged to create a single annotation per gene ID. SEQEM [18]
was used to assign the most probabilistic location of multireads.
The number of reads mapping to exons were summed per gene
and normalized by the number of exonic base pairs and total number
of mapped reads per sample, where appropriate. We inspected the
interquartile ranges of expression in both the tumor and normal
and decided that “expression” should be defined as ≥10 reads
mapped per kilobase per million reads mapped (RPKM). The small
RNA sequencing library preparation was separate, so we repeated the
above on the resulting data that we used to inspect miRNA, resulting
in an expression threshold of ≥3.
Functional Annotation
Gene ontology and pathway analysis for protein-coding genes
was completed using the DAVID functional annotation tool [19].
Functional analysis of miRNA was completed using TAM (Tool
for Analysing miRNA) [20].
Correlation Analysis
Spearman correlation coefficient, and significance thereof, between
ploidy and either tumor expression or fold change in expression (tumor/
normal) was calculated in R for all genes (or genomic windows) that
were expressed in the tumor or in both cell lines, respectively.
Transcription across Breakpoints
A bespoke python script was created to assemble a 600-bp sequence
that centered on the each predicted breakpoint and output these in fasta
format. The file was then used as a reference set and bowtie alignments
identified all reads that aligned to the breakpoints but not anywhere on
the human reference genome. To be considered as a transcribed break-
point, at least three unique reads had to span the breakpoint by more
than three bases either side.
Results
The LUDLU-1 genome was sequenced to an average coverage of 61×
and the matched lymphocyte cell line to 55×. A total of 600.4 million
strand-directional LUDLU-1 RNA reads aligned to the human ge-
nome, and 169,000 additional small reads aligned to known miRNA.
To provide a baseline from which to quantify tumor-specific changes
in expression, we also sequenced the full transcriptome of h-TERT
transformed normal bronchial epithelium, the cell line for which we
named LIMM-NBE1. A total of 700.8 million strand-directional
LIMM-NBE1 RNA reads aligned to the genome and 185,000 small
reads to known miRNA. We also sequenced the genome of LIMM-
NBE1 at low coverage (0.06×) to inspect the copy number profile
and found two distinct abnormalities: gain of one copy of chromosome
20 and one copy of 1q (Figure W1). We believe these abnormalities
are a consequence of h-TERT transformation, based on the observation
of similar structural variants, and gain of chromosome 20 specifically,
on transformation of a series of other human bronchial epithelium
samples [21]. Transcription levels in LIMM-NBE1 in these regions
may, therefore, differ from a truly diploid cell line. To assess whether
the noted copy number abnormalities in LIMM-NBE1 affected the
genome-wide transcriptome research, detailed below, we performed
our analysis both with and without those regions included and found
there to be no significant difference in the conclusions drawn. One
limitation of our approach is a lack of biologic replicates, meaning
we are unable to inspect differential gene expression between our
samples. This does not inhibit an integrated analysis of the genomic
and transcriptomic data but does mean that differences in expression
between LUDLU-1 and LIMM-NBE1 can only be denoted as fold
change, with no indication of the significance of the difference outside
of these samples.
Aneuploidy is a common occurrence in cancer genomes and can be
a mechanism for regulating expression of the genes involved in disease
progression [22–24]. Our high-resolution copy number analysis in
LUDLU-1 enabled comparison with previously characterized lung
SCC genomic landscapes, and the RNAseq data enabled concurrent
expression quantification in regions of interest.
Candidate Genes in Regions of Common Copy Number
Alteration in Lung SCCs
LUDLU-1 is largely tetraploid (Figure 1) with many anomalies pre-
viously characterized in lung SCC cohorts [25–30]. Table 1 lists these
commonly altered genomic regions and the previously suggested can-
didates of carcinogenesis, including expression in the normal and the
tumor cell line, within them (except for homozygous deletions where
all deleted genes are listed). The largest tumor-associated gain in
expression is for SOX2 [ENSG00000181449], a candidate oncogene
that can confer stem cell–like qualities to cancer cells and whose
amplification has been shown to be a key event in the formation of
SCC of the lung [31–33].
LUDLU-1 contains two regions of homozygous deletion, both
within 9p. The only involved gene that is expressed in the nor-
mal bronchial epithelium is PTPRD [ENSG00000153707], which
encodes a protein tyrosine phosphatase receptor indicated to have
tumor suppressor function in laryngeal SCCs and lung cancer (with
homozygous deletions observed in adenocarcinomas and small cell
and large cell lung cancer lines) and for which tumor suppressor
function has been shown in neuroblastoma [34–36]. This region
also contains CDKN2A [ENSG00000147889] and CDKN2B
[ENSG00000147883], which encode p16 and p15 cyclin-dependent
kinase inhibitors, respectively. These are known tumor suppressor
genes whose products are involved in the onset of cellular senescence
[37]. Homozygous deletion of this area has previously been observed
in 26% and 36% of lung SCCs in two separate studies and is sig-
nificantly associated with never smokers compared to current, or
previous, smokers [38–40]. The somatic point mutational profile
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Figure 1. Two depictions of the lung SCC cell line (LUDLU-1) genome. (A) Visualization through multicolor fluorescence in situ hybridiza-
tion. This image is the chromosomes from a single cell. The hybridized probes are colored according to their chromosome of origin,
with each chromosome name being written in the corresponding color. (B) The genome averaged over all cells in the sample, visualized
through a Circos plot. The outer track consists of chromosome ideograms with centromeres in red. Starting from the inner track, there is
sequential depiction of structural rearrangements (intrachromosomal variants appear as short gray lines, whereas interchromosomal
variants appear as arcs across the inner circle) and copy number changes (shaded gray is the most common, tetraploid, with dark
and light orange showing gain and loss, respectively). Allelic ratios are represented by a black line, superimposed over copy number,
with a return to baseline indicating loss of heterozygosity.
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for LUDLU-1 is not consistent with tobacco exposure, leading us
to propose a non-tobacco exposure–based etiology for this specific
SCC (L. Stead, S. Berri, H.M. Wood, P. Egan, C. Conway, C. Daly,
R. Chalkley, O. Belvedere, K. Papagiannopoulos, K. MacLennan and
P. Rabbitts, submitted for publication) [8].
To identify additional candidates, we inspected the fold change in
expression between LIMM-NBE1 and LUDLU-1 for every gene within
the commonly altered regions outlined in Table 1 (Tables W1 andW2).
Regions of gain. In total, 10,218 genes lie in the commonly am-
plified genomic regions, with seven expressed more than 1000-fold
higher in the tumor than the normal. Five of these have previously
been associated with lung carcinogenesis, although one, PON1
[ENSG00000005421], an antioxidant paraoxonase that scavenges
endogenous free radicals, has previously been observed at decreased
levels in tumors [41]. Elevated expression of PON1 in LUDLU-1
may be a result of increased levels of endogenous reactive oxygen
species in this cell line, specifically, a phenomenon for which we
have devised a hypothesis (L. Stead, S. Berri, H.M. Wood, P. Egan,
C. Conway, C. Daly, R. Chalkley, O. Belvedere, K. Papagiannopoulos,
K. MacLennan and P. Rabbitts, submitted for publication). The re-
maining candidates with previous lung cancer associations are ELF3
[ENSG00000163435], which can be overexpressed in lung carcinomas
and has the ability to regulate lung cell proliferation and differentia-
tion in response to bronchial epithelial cell damage in mice [42,43];
STEAP4 [ENSG00000127954], homologous to a gene that is over-
expressed in lung SCCs and whose protein products are candidates
as tumor-associated antigens [44]; RAB25 [ENSG00000132698], a
known oncogene that is part of a 12-gene subset whose expression pat-
tern is able to classify the lung cancer histologic subtypes, with apparent
increased protein product levels observed in SCC especially [45]; and
KIAA1324L [ENSG00000164659], homologous to a gene that is over-
expressed in metastatic lung cancers and able to stop cells from under-
going apoptosis in response to stress [46,47]. The remaining genes
within commonly amplified regions that exhibit large increased ex-
pression in LUDLU-1 are GRHL2 [ENSG00000083307] and RIMS2
[ENSG00000176406]. While these genes reside in 8q, a region that is
amplified, overall, in LUDLU-1, they are both present at three copies,
i.e., lower than the tetraploid state that is considered “normal” for this
cell line. GRHL2 is an oncogenic candidate owing to its ability to
Table 1. Copy Number Anomalies in LUDLU-1 that Have Been Previously Observed in Lung SCCs.
LUDLU-1 Copy
Number Anomaly











Gain 3q 76% (258) [25–30] ENSG00000114200 BCHE 7 (1:6) 13 2 7.83
ENSG00000163581 SLC2A2 7 (1:6) 0 0 0
ENSG00000085276 EVI1 7 (1:6) 127 294 0.43
ENSG00000136603 SKIL 7 (1:6) 35 78 0.45
ENSG00000114346 ECT2 8 (1:7) 1036 390 2.66
ENSG00000121879 PIK3CA 6 (1:5) 374 273 1.37
ENSG00000113916 BCL6 6 (1:5) 63 69 0.92
ENSG00000114315 HES1 6 (1:5) 72 46 1.58
ENSG00000181449 SOX2 6 (1:5) 11 0 108.91
5p 56% (229) [25–28,30] ENSG00000145604 SKP2 7 (1:6) 358 235 1.52
ENSG00000168621 GDNF 7 (1:6) 0 0 1.01
8q 44% (229) [25–28,30] ENSG00000136997 MYC 5 (1:4) 104 183 0.57
7p 43% (156) [25,26,28] ENSG00000106268 NUDT1 5 (0:5) 19 8 2.29
ENSG00000146648 EGFR 8 (2:6) 2120 935 2.27
1q 49% (51) [25,30] ENSG00000213190 AF1Q 6 (1:5) 5 6 0.85
ENSG00000143549 TPM3 6 (1:5) 1314 728 1.81
ENSG00000163131 CTSS 6 (1:5) 15 2 7.19
ENSG00000162924 REL 4 (0:4) 53 49 1.09
20p 14% (135) [25,27,28] ENSG00000172264 MACROD2 7 (1:6) 21 7 2.80
7q 35% (144) [26,28] ENSG00000105851 PIK3CG 7 (1:6) 0 0 0
ENSG00000106462 EZH2 5 (1:4) 228 151 1.51
ENSG00000105989 WNT2 5 (1:4) 0 0 1.02
ENSG00000105976 MET 5 (1:4) 529 971 0.55
20q 29% (144) [26,28] ENSG00000101412 E2F1 4 (1:3) 12 25 0.50
Loss 3p 53% (229) [25–28,30] ENSG00000189283 FHIT 2 (0:2) 4 9 2.10
ENSG00000068028 RASSF1 2 (0:2) 4 16 4.47
ENSG00000134086 VHL 2 (0:2) 9 12 1.26
5q 34% (195) [25,26,28,30] ENSG00000134982 APC 2 (0:2) 45 95 2.08
8p 33% (195) [25,26,28,30] ENSG00000149557 FEZ1 4 (1:3) 60 334 5.60
ENSG00000120875 DUSP4 2 (0:2) 19 168 8.78
13q 38% (195) [25,26,28,30] ENSG00000139687 RB1 3 (1:3) 484 832 1.72
17p 20% (12) [25] ENSG00000141510 TP53 2 (0:2) 262 181 0.69
18q 22% (67) [25,26] ENSG00000187323 DCC 2 (0:2) 0 0 0.98
4q 36% (128) [26,27] ENSG00000163629 PTPN13 2 (0:2) 500 842 1.68
9p 34% (135) [25,27,28] ENSG00000197919 IFNA1 1 (0:1) 0 0 0
Loss (homozygous) chr9:8.65-10.1Mb N/A N/A ENSG00000147889 CDKN2A N/A 0 0 0
ENSG00000147883 CDKN2B 0 0 0
ENSG00000176399 DMRTA1 0 2 0
ENSG00000234840 FLJ35282 0 0 0
chr9:21.85-23.05Mb N/A N/A ENSG00000153707 PTPRD N/A 0 11 110.00
†Fold change is given as tumor/normal for regions of gain and normal/tumor for regions of loss.
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inhibit expression of death receptors, thereby inhibiting apoptosis [48].
RIMS2, to our knowledge, has not been associated with carcinogenesis.
It is known to encode a protein involved in exocytosis that can interact
with Rab3, a member of the Rab family of guanine triphosphatases
(GTPases), which have been implicated in cancer but not to the extent
of the Ras and Rho GTPase families [49]. Gene ontology analysis of all
genes within the specified, commonly amplified regions in lung SCC
revealed significant (hypergeometric, false discovery rate [FDR] <
0.05) enrichment of the biologic processes of keratinization and epi-
thelial, epidermal, and keratinocyte differentiation. The presence of
keratin “pearls” is one of the markers that pathologists use to assign
an SCC histology to lung cancer.
Regions of loss. Cumulatively, the regions that commonly show a
reduction in copy number for lung SCC contain 8071 genes, a subset
with significant (hypergeometric, FDR < 0.05) enrichment in the cel-
lular component of extracellular space, biologic processes of cell-cell
signaling and adhesion, and molecular function of cytokine activity
and binding. Cytokines are intercellular signaling molecules, whose ex-
pression and activity is often altered during carcinogenesis with pleio-
tropic effects [50]. Increased expression of cytokines in lung SCC cell
lines has been previously recorded [51]. Nine of the 8071 genes are
expressed 1000-fold less in the tumor than the normal bronchial epi-
thelium, and in concurrence with the gene ontology analysis, four are
associated with the extracellular matrix: POSTN [ENSG00000133110],
SPARC [ENSG00000113140], VCAN [ENSG00000038427],
and FBN2 [ENSG00000138829]. The five additional highly under-
expressed genes are FAT4 [ENSG00000196159] that encodes a cadherin
that has been associated with tumor suppressor function in breast
cancer [52]; EDNRA [ENSG00000151617] that is a homologue of a
gene observed to undergo hypermethylation in lung cancers [53];
ODZ2 [ENSG00000145934] that resides in 5q and encodes a pro-
tein called Teneurin-2, which has been shown to be a membrane-
bound transcriptional regulator with the potential to switch neural
cells from a stage of growth to one of differentiation; and both AREG
[ENSG00000109321] and AREGB [ENSG00000205595] that encode
amphiregulins. Amphiregulins are epidermal growth factors that bind
and activate the receptor epidermal growth factor receptor (EGFR), a
signaling pathway that is activated specifically in some lung adeno-
carcinomas [54]. The apparent down-regulation of these genes in lung
SCC again emphasizes the differences in the underlying biology of the
two main non–small cell lung cancer histotypes [55].
Finally, using the list of 10,961 protein-coding genes that were
expressed in either LUDLU-1 or LIMM-NBE1 as background, we
looked for pathway enrichment in the subset of genes exhibiting a fold
change in expression of 10 or more, irrespective of whether the gene
was upregulated or downregulated in the tumor. Significant enrich-
ment (FDR < 0.05) was observed for pathways involved in extracellular
matrix-receptor interactions, focal adhesion, and integrin cell–surface
interactions. This is consistent with the functional annotation enrich-
ment in the subset of genes in regions of loss. Additionally, pathways
involved in hemostasis were enriched. Hemostasis will be affected
during sustained angiogenesis, one of the hallmarks of cancer in which
integrin signaling also plays a known role [56]. This implies that angio-
genic regulation is a particularly important process in LUDLU-1 cells.
Thirteen members of the phosphatidylinositol 3-kinase (PI3K) pathway
exhibited more than 10-fold change in expression between the SCC
and the bronchial epithelial cell line, but the enrichment in members
of this pathway was not significant after multiple testing correction.
Each gene candidate highlighted in the preceding analysis is protein
coding. However, there are several types of transcript besides those with
protein-coding capacity [57]. The past decade has brought an increased
interest in characterizing functional non-coding RNA (ncRNA), and
their associations with carcinogenesis are now well documented [58–
60]. The delineation of transcripts outside of the 2% of the genome
that encode protein is also still ongoing, with much of the transcrip-
tome remaining to be fully characterized. To overcome these issues
and inspect the effect of copy number on transcription in a genome-
wide manner, we decided to investigate the correlation between ploidy
and expression using 50-kb windows, as well as in a gene-based manner
but within subtypes of functional transcript.
Genome-wide Analysis of Copy Number Effects
on Transcription
We analyzed the effect of ploidy on transcription in two different
ways; we assessed the correlation between copy number in LUDLU-1
and either 1) absolute expression or 2) the fold change in expression
between LUDLU-1 and LIMM-NBE1. Significant (Spearman P < .05)
but weak correlations were observed, using both approaches, when as-
sessing expression within the 50-kb windows, protein-coding genes,
antisense transcripts, long intergenic ncRNA (lincRNA), and miRNA
but not for small nucleolar RNA (snoRNA), small nuclear RNA, or
pseudogenes. Figure 2 displays the relative values of the correlation co-
efficients. The largest difference in the coefficients obtained by the two
expression metrics is for the protein-coding genes, where copy number
appears to have a larger effect on fold changes in expression than abso-
lute expression values. Taking proteins as the “analogue output” of the
genome [61], this is an interesting observation that implies that copy
number affects protein levels in a more complex manner than simple
gene dosage, perhaps through the regulatory networks that govern pro-
tein production. LincRNAs are intuitive candidates for modulators
of this effect owing to their roles in both pre-transcriptional (through
chromatin remodeling and gene silencing) and post-transcriptional (by
binding to and targeting proteins) regulation of mRNA [62]. We, thus,
noted that lincRNAs are the only subtype in which their absolute tumor
expression correlates more with copy number than the fold change in
expression between tumor and normal does. Boxplots of expression
levels and fold changes observed at one to six copies of 50-kb windows,
all genes, protein-coding genes, and lincRNA genes (FigureW2) reiterate
that copy number correlates more with changes in expression between
the normal bronchial epithelium and the tumor cell lines than with the
absolute expression in the latter.
To see how the expression levels of each functional subtype of
transcript varied, irrespective of copy number, we also inspected our
RNAseq data in isolation.
Functional Transcripts Exhibit Variable Expression Patterns
Average expression levels per functional transcript class are given
in Table 2 and Figure 3. Only snoRNA exhibited an overall change
in the mean expression level with a significant decrease (paired t test,
P < .05) in the tumor compared to the normal. An expression signa-
ture of six snoRNA has been proposed as a biomarker for non–small
cell lung cancer with all upregulated in tumors [63]. Five of these had
two-fold to seven-fold increased expression in LUDLU-1 compared
to LIMM-NBE1, despite our overall observed trend of decreased
transcription levels for snoRNA. The remaining biomarker snoRNA
was expressed at four orders of magnitude lower, in both samples,
than the other five.
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The correlation coefficients for expression of the various transcript
classes between samples denote whether the genes are ranked in a simi-
lar order (Table 2). miRNA have the lowest correlation coefficient at
0.12, indicating that this class of transcript undergoes the largest
change in expression pattern. Of the 591 miRNA for which we ob-
served expression in either sample, only 48% were expressed in both,
with 32% being uniquely expressed in the bronchial epithelium and
20% unique to the SCC. There are separate sequencing library prepara-
tion protocols for the distinct capture of small (<30 bp) RNA molecules.
On sequencing the additional libraries that we made for LIMM-NBE1
and LUDLU-1 using these specific protocols, the coefficient increased
to 0.37 but remains the lowest of the subtypes. miRNA have been
shown to stabilize cell states, whether they be quiescent or proliferative,
prompting researchers to propose that these transcripts confer robust-
ness in response to cellular stresses [64]. An overhaul in miRNA expres-
sion pattern, as indicated by the low correlation coefficient between
our cell lines, may have been causal (potentially offering therapeutic
targets) or consequential (potentially offering diagnostic biomarkers)
to the tumorigenic progression of LUDLU-1 by facilitating or stabiliz-
ing transitory cell states. The let-7 family of miRNA is believed to act
as tumor suppressors in non–small cell lung cancer, with decreased
expression correlating with poor prognosis [65,66]. Our data show that,
of the 13 let-7 miRNA, the normalized read count in our normal
epithelial cell line was greater than that in tumor with three members
exhibiting a greater than 10-fold decrease in the SCC sample (Table 3).
miRNA has also been successfully used to distinguish lung SCC from
adenocarcinoma, implying a role in the differing biologic processes
that underlie these subtypes [67,68]. To expand our analysis, we in-
spected the enrichment of clusters, families, and functions within the
55 miRNA that exhibited an expression fold change of 10 or more
between samples. While no findings were significant after multiple
testing corrections were applied, we note that the hsa-let-7e cluster
and miR-99 family both had unadjusted P values of <.05.
The above quantification of expression using RNAseq data involves
counting the number of reads that map to annotated regions of tran-
scription within the reference genome. However, structural rearrange-
ments, which commonly occur during carcinogenesis and constitute
part of the somatic mutational profile of each tumor, can be identified
through whole-genome sequencing, and concurrent RNAseq can then
inspect and quantify transcription across newly fused genomic regions.
Such structural rearrangements can be key pathogenic drivers of cancer
and, thus, provide therapeutic targets, as has been observed for lung
adenocarcinoma [2,69].
Transcribed Structural Rearrangements
We identified 171 large (>100 bp) somatic structural variants in
LUDLU-1: 66 deletions, 47 inversions, 29 translocations, and 29 dupli-
cations. More than half interrupt annotated genes. This is consistent
with observations in whole-genome sequencing of both a small cell
lung cancer and a lung adenocarcinoma cell line, where 64% and
63% of structural variants interrupted annotated genes, respectively
[8,9]. However, we only found evidence of transcription (at least three
uniquely aligned tumor RNA reads) across six (Figure 4). Deletion
of bases 60,392,103 to 60,650,744 in 3p removes exon 5 of FHIT
[ENSG00000189283] (Figure 4A), creating a frameshift and remov-
ing the 5′ untranslated region (UTR) for all known isoforms. Transcrip-
tion through this breakpoint, while on the same strand as FHIT, is,
thus, unlikely to be translated. FHIT is a tumor suppressor gene and
deletion of exon 5 has been observed previously in thyroid, digestive
tract, and ovarian tumors [70–72]. RNA reads map throughout the de-
letion, implying that one of the two copies of FHIT in LUDLU-1 retains
the region. However, tumor expression is six-fold lower than that in
the normal bronchial epithelium.
A smaller deletion in 6p involves bases 26,161,020 to 26,222,257.
Transcription through this breakpoint is on the same strand as
HIST1H2BD [ENSG00000158373], a gene that the deletion affects
by removing exon 2 (Figure 4B). Seven additional histone genes lie fully
Figure 2. Dosage effects on expression. Correlation coefficients between copy number and either absolute tumor transcript expression
(gray bars) or fold change between tumor and normal (black bars) for different functional transcript classes. Each coefficient is significant
(Spearman P < .05).
Table 2. Average Expression Levels for Different Functional Transcripts.
Type of RNA Number of
Transcripts
Mean RPKM (Median) Correlation
Coefficient
Normal Tumor
Protein coding 17830 107 (14) 100 (12) 0.67
Pseudogene 410 12.7 (0.3) 12.2 (0.07) 0.87
Antisense 2254 12.7 (0.034) 21.7 (0.01) 0.72
lincRNA 2290 0.7 (0.016) 0.9 (0.02) 0.62
miRNA 591 4.4 (0.09) 17 (0.08) 0.12
snoRNA 1002 2215* (0.74) 1530* (0.54) 0.87
Small nuclear RNA 899 86 (0.025) 147 (0.08) 0.73
*Significant (paired t test, P < .05) difference in the mean expression level.
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within this LUDLU-1 deletion on 6p: HIST1H2BE, HIST1H3D,
HIST1H2BG, HIST1H2AE, HIST1H2BF, HIST1H4D, and
HIST1H4E. Tumor ploidy in this region is four. There are modest
decreases in tumor expression, compared to the normal bronchial epi-
thelium, for six of the seven histone genes, but HIST1H2BE expres-
sion in LUDLU-1 is 40-fold lower than LIMM-NBE1. The 6p
histone cluster has not been implicated previously in carcinogenesis.
On 7q, deletion of exon 4 of ATP5J2 [ENSG00000241468] is adjacent
to a ∼100-bp inversion in a neighboring intron (Figure 4C). Transcrip-
tion through this breakpoint is from the same strand as ATP5J2 but
also that of a known read-though transcript that starts with ATP5J2
and continues to PTCD1 [ENSG00000106246], which creates a con-
joined gene ATP5J2-PTCD1 [ENSG00000248919]. Conjoined genes
can be functional, with potential regulatory affects on the constituent
genes. The somatic rearrangement in LUDLU-1 may favor expression
of the read-through owing to the removal of the final exon from ATPJ52
[73,74]. ATP5J2 encodes a subunit of complex V of the respiratory
chain, while PTCD1 alters the activity of complex IV [75]. Aberrant,
dual regulation of these genes, by the mutated read-through transcript,
could affect oxidative phosphorylation in ways that may be carcino-
genic, as reviewed in Lemarie and Grimm [76].
A much larger inversion is present in LUDLU-1 on 12q, where base
pairs 104,509,980 to 104,715,714 have been duplicated and inverted
at position 104,700,066 (Figure 4D). This has three main effects:
complete disruption of TXNRD1 [ENSG00000198431], amplifi-
cation of EID3 [ENSG00000255150], and aberrant, antisense tran-
scription of NFYB [ENSG00000120837]. The latter is owing to
transcription through the inversion that results in expression of the
complementary strand to the nuclear transcription factor gene. Sense
expression of NFYB is the same in LUDLU-1 and the normal bron-
chial epithelium, whereas antisense expression is 25-fold higher in the
tumor. This could lead to regulation of the NFYB mRNA and, thus,
altered protein levels within the tumor [77]. NFYB encodes a sub-
unit that forms complexes with, and alters the function of, p53 [78].
Interestingly, we also found a non-synonymous somatic mutation in
TP53 [ENSG00000141510] that results in a lack of a functional
copy of p53 in LUDLU-1 (L. Stead, S. Berri, H.M. Wood, P. Egan,
C. Conway, C. Daly, R. Chalkley, O. Belvedere, K. Papagiannopoulos,
K. MacLennan and P. Rabbitts, submitted for publication). Mutant
p53 is able to associate with the NF-Y protein complex, of whichNFYB
encodes a subunit, leading to a variety of cell cycle and apoptotic
defects that are not fully characterized [79]. TXNRD1 expression is
approximately halved in the tumor compared to the normal cell line.
This gene encodes a pyridine nucleotide oxidoreductase, which can
help protect the cell against oxidative stress. Amplification of EID3, a
potential inhibitor of cell differentiation, in LUDLU-1 is concurrent
with a 12-fold increase in its expression [80].
The RNA reads resulting from transcription through a structural mu-
tation on 6q, in which bases 65,693,384 to 71,306,346 are removed,
indicate an immediately adjacent inversion up to base 71,306,397
(Figure 4E). The latter region is downstream from a predicted protein-
coding gene: C6orf57 [ENSG00000145079]. The deletion includes
BAI3 [ENSG00000135298], LMBRD1 [ENSG00000168216],
COL19A1 [ENSG00000082293], FAM135A [ENSG000000082269],
and up to intron 14 of EYS [ENSG00000188107], which is predicted
to disrupt the codon usage in EYS translation if the aberrant transcript
was attempted. Despite this deletion, the region is amplified, which
may account for modest increases in expression levels of all genes
involved in the structural variation; a 2-fold increase is observed for
LMBRD1 and FAM135A, 6-fold for COL19A1, and 10-fold for BAI3.
The final, transcribed structural variant is an inversion that creates
a potential fusion gene (Figure 4F ). It is located on 11q and causes
a read-through from intron 3 of FRMD8 [ENSG00000216391],
Figure 3. Functional transcript expression. Mean expression levels for different functional transcript classes in both the normal bronchial
epithelium cell line (gray bars) and lung squamous cell tumor cell line (black bars). Expression is quantified as RPKM.
Table 3. Reads Mapping to let-7 Family miRNA Genes, Normalized by Sequencing Depth.
miRBase ID Normalized Read Count Fold Change (N/T)
LUDLU-1 LIMM-NBE1
hsa-let-7c 51.7 2436.8 47.1
hsa-let-7b-5p 3796.2 67964.9 17.9
hsa-let-7e-5p 100.0 1417.3 14.2
hsa-let-7e-3p 0.9 8.1 9.4
hsa-let-7a-5p 1650.2 14399.0 8.7
hsa-let-7g-5p 544.0 1398.7 2.6
hsa-let-7f-5p 172.4 428.0 2.5
hsa-let-7b-3p 13.8 15.1 1.1
hsa-let-7d-5p 224.2 242.4 1.1
hsa-let-7a-2-3p 0.0 1.2 Inf
hsa-let-7a-3p 0.0 1.2 Inf
hsa-let-7i-5p 2572.8 1018.3 0.4
hsa-let-7d-3p 329.4 114.8 0.3
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starting at base pair 65,157,970, into position 65,150,150, which
is immediately before the transcription, start site for SLC25A45
[ENSG00000162241]. These genes are usually on different strands,
but the inversion causes them to locate on the same strand, and it is
from that which the LUDLU-1 RNAseq reads have originated. It is
not possible to predict whether this novel transcript would be capable
of producing a chimeric protein using the RNAseq data. FRMD8
encodes an uncharacterized protein that contains a single FERM
domain, usually involved in localizing proteins to the plasma mem-
brane [81], while SLC25A45 codes for a transmembrane solute car-
rier that resides within the mitochondrial inner membrane [82].
Discussion
SCCs of the lung have extremely complex karyotypes. Nonetheless, in
contrast, particularly to the adenocarcinoma subtype, specific chromo-
somal abnormalities occur frequently. Deletion or loss of heterozygosity
of 3p and gain or amplification of distal 3q are common hallmarks of
this subtype [83,84]. Interestingly, and of potential clinical value, the
squamous subtype of tumors at other sites such as esophagus, head and
neck, and cervix also carry the 3p loss/3q gain motif [85]. These, and
other common genomic features, may be due to underlying similarities
in etiology, suggesting that possible drug targets identified in one tumor
type could be transferable to other organ sites with the same SCC
histology. Our integrated approach has allowed us to probe these com-
monly altered regions in a lung SCC cell line, delineating the break-
points to base pair resolution and prioritizing a list of candidate genes
based on the somatic effects on transcription. Several known lung
cancer-associated genes were highlighted in our analysis, such as SOX2,
ELF3, and RAB25, indicating that other highlighted genes that do
not have previous lung cancer, such as GRHL2 and RIMS2, are worth
further inspection using different approaches.
Figure 4. Transcribed breakpoints in the lung SCC cell line (LUDLU-1). Each of A–F depicts a separate event. The reference genome
is denoted by a gray, demarcated double line with a double-headed arrow above to indicate scale. Gene regions are indicated below
the double line in blue with vertical blocks representing exons and horizontal lines: introns. The name of each gene is given where
appropriate. Underneath the genes, the transcribed breakpoints are depicted; deletions are denoted by red blocks and inversions by
blue arrows, indicating their reversed direction in the novel genome made by LUDLU-1 structural variants.
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We designed the RNAseq for this work to ensure that both coding
and ncRNA species were investigated in a strand-specific manner. This
allowed the transcriptome to be probed in great detail, including the
ability to distinguish sense and antisense transcription. An example of
a benefit from this approach was our ability to detect an inversion in
12q that results in a large increase in antisense transcription, which can
ultimately affect protein levels, of NFYB, a gene that encodes part of a
complex that associates with p53. Non–strand-directional methods
would have attributed this antisense expression as increased NFYB
mRNA production, giving a false expression level reading for the gene
and potentially leading to a hypothesis about the gene’s involvement in
carcinogenesis that could, ultimately, be rejected.
Using an additional small RNA sequencing protocol enabled us to
capture information on miRNA. While a lack of biologic replicates
negates a robust analysis of differential expression, using fold change
alone, we were able to highlight the let-7 and miR-99 subfamilies,
members of which have been associated with tumor suppressor func-
tion in non–small cell lung cancer [65,86]. Furthermore, we showed
that, across transcript classes, miRNA expression values are the least
correlated between LIMM-NBE1 and LUDLU-1 cell lines. miRNA
has been shown to form complex regulatory networks, able to act as
either tumor suppressors or oncogenes, depending on their targets
[87]. As such they have become an important area in cancer research
in recent years, revealing their potential use in diagnostics and as ther-
apeutic targets [68,88,89]. The latter is particularly important for lung
SCC. Our analysis show that miRNA undergoes the largest change in
expression profile between the normal bronchial epithelial and the
tumor cell lines, potentially indicative of the involvement of miRNA
early in the disease process, highlighting the importance of continued
and expanded research into the involvement of these small RNA in
lung carcinogenesis.
While this paper was under review, two large lung cancer studies
were reported. TCGA published their findings on 178 lung SCCs,
which included analysis of genome, exome, mRNA, and miRNA
sequencing data [90]. Their results confirmed the significance in lung
SCC of many of the copy number alterations discussed herein, also
highlighting both SOX2 amplification and CDKN2A homozygous
deletion. Several pathways were highlighted by TCGA publication
as yielding potential therapeutic targets: PI3K/AKT, the receptor
tyrosine kinases, and RAS. We note that the PI3K pathway was
highlighted in our single-sample analysis, although it was not sig-
nificant following multiple testing. Additional therapeutic targets that
were indicated by TCGA study are the fibroblast growth factor recep-
tors (FGFRs). While FGFRs were not highlighted by our analyses,
we note that the miRNA that we observed to have undergone the
largest fold changes in expression was somewhat enriched for miR-99
family members and that a direct association between hsa-miR-99b
[ENSG0000007550], acting as a tumor suppressor in non–small cell
lung cancer, and FGFR3 [ENSG00000068078] has been observed
[86]. A study of 183 lung adenocarcinomas that reported the findings
of genome and exome sequencing data analysis was also published
[91]. One of the key similarities between the two studies, and ours,
was the involvement of CDKN2A. However, no other genes high-
lighted in the adenocarcinoma publication were specifically extracted
during our analysis, further suggesting the biologic differences between
adenocarcinoma and SCC of the lung. In their discussion, the authors
note that they believe that combined analyses, such as our approach
of integrating genomic and transcriptomic data, will improve the
annotation of important genes in carcinogenesis in the future.
The cost of next-generation sequencing is decreasing, but there is
still choice to be made by researchers as to whether funds are better
used to obtain detailed integrated information on single, or few,
samples or focused information on a larger number of samples. We
believe that the solution depends on whether the research is hypothesis
driven or exploratory. This study is an example of the latter and we,
herein, have shown that integrating high coverage genome and tran-
scriptome data for a single sample can lead to valuable hypotheses.
Both approaches are valuable, perhaps as part of iterative research in
which exploratory data drive hypotheses, tested by additional data.
Acknowledgments
We thank Rick Tearle, a senior field applications scientist from Com-
plete Genomics, for useful discussions on data analysis and the use
of the company’s proprietary tools. We also thank R.A. Weinberg,
D. Trono, and I. Verma for supplying the plasmids through Addgene
for the lentivirus used in the LIMM-NBE1 transformation.
References
[1] Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M,
Lopez-Vivanco G, Isla D, Provencio M, et al. (2009). Screening for epidermal
growth factor receptor mutations in lung cancer. N Engl J Med 361, 958–967.
[2] Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara
S-I, Watanabe H, Kurashina K, Hatanaka H, et al. (2007). Identification of the
transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448,
561–566.
[3] Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan
BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. (2004). Activating
mutations in the epidermal growth factor receptor underlying responsiveness of
non–small-cell lung cancer to gefitinib. N Engl J Med 350, 2129–2139.
[4] Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong
P, Han B, Margono B, Ichinose Y, et al. (2009). Gefitinib or carboplatin-paclitaxel
in pulmonary adenocarcinoma. N Engl J Med 361, 947–957.
[5] Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T,
Satouchi M, Tada H, Hirashima T, et al. (2010). Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring mutations of the
epidermal growth factor receptor (WJTOG3405): an open label, randomised
phase 3 trial. Lancet Oncol 11, 121–128.
[6] Janssen-Heijnen MLG and Coebergh J-WW (2001). Trends in incidence and
prognosis of the histological subtypes of lung cancer in North America, Australia,
New Zealand and Europe. Lung Cancer 31, 123–137.
[7] Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca
SM, Barber T, Ptak J, et al. (2007). The genomic landscapes of human breast
and colorectal cancers. Science 318, 1108–1113.
[8] Pleasance ED, Stephens PJ, O’Meara S, McBride DJ, Meynert A, Jones D, Lin
M-L, Beare D, Lau KW, Greenman C, et al. (2010). A small-cell lung cancer
genome with complex signatures of tobacco exposure. Nature 463, 184–190.
[9] Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J, Yue P, Zhang Y, Pant
KP, Bhatt D, et al. (2010). The mutation spectrum revealed by paired genome
sequences from a lung cancer patient. Nature 465, 473–477.
[10] Rabbitts P, Douglas J, Daly M, Sundaresan V, Fox B, Haselton P, Wells F,
Albertson D, Waters J, and Bergh J (1989). Frequency and extent of allelic loss
in the short arm of chromosome 3 in nonsmall-cell lung cancer.Genes Chromosomes
Cancer 1, 10.
[11] Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, Kermani BG,
Carnevali P, Nazarenko I, Nilsen GB, Yeung G, et al. (2010). Human genome
sequencing using unchained base reads on self-assembling DNA nanoarrays. Science
327, 78–81.
[12] Wood HM, Belvedere O, Conway C, Daly C, Chalkley R, Bickerdike M,
McKinley C, Egan P, Ross L, Hayward B, et al. (2010). Using next-generation
sequencing for high resolution multiplex analysis of copy number variation from
nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens.
Nucleic Acids Res 38, e151.
[13] Hackenberg M, Sturm M, Langenberger D, Falcón-Pérez J, and Aransay A
(2009). miRanalyzer: a microRNA detection and analysis tool for next-generation
sequencing experiments. Nucleic Acids Res 37, W68–W76.
1084 Transcriptional Consequences of Lung SCC Variants Stead et al. Neoplasia Vol. 14, No. 11, 2012
[14] Langmead B, Trapnell C, Pop M, and Salzberg S (2009). Ultrafast and memory-
efficient alignment of short DNA sequences to the human genome. Genome Biol
10, R25.
[15] Complete Genomics Incorporated (2012). Available at: http://cgatools.sourceforge.
net/docs/1.3.0/cgatools-methods.pdf. Accessed April 8, 2012.
[16] Gusnanto A, Wood HM, Pawitan Y, Rabbitts P, and Berri S (2012). Cor-
recting for cancer genome size and tumour cell content enables better estimation
of copy number alterations from next-generation sequence data. Bioinformatics
28, 40–47.
[17] Flicek P, Amode MR, Barrell D, Beal K, Brent S, Chen Y, Clapham P, Coates
G, Fairley S, Fitzgerald S, et al. (2011). Ensembl 2011. Nucleic Acids Res 39,
D800–D806.
[18] Paşaniuc B, Zaitlen N, and Halperin E (2011). Accurate estimation of expression
levels of homologous genes in RNA-seq experiments. J Comput Biol 18, 459–468.
[19] Huang DW, Sherman BT, and Lempicki RA (2009). Bioinformatics enrichment
tools: paths toward the comprehensive functional analysis of large gene lists.
Nucleic Acids Res 37, 1–13.
[20] Lu M, Shi B, Wang J, Cao Q, and Cui Q (2010). TAM: a method for enrich-
ment and depletion analysis of a microRNA category in a list of microRNAs.
BMC Bioinformatics 11, 419.
[21] Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, Peyton M, Zou Y,
Kurie JM, DiMaio JM, et al. (2004). Immortalization of human bronchial
epithelial cells in the absence of viral oncoproteins. Cancer Res 64, 9027–9034.
[22] Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E,
Ringner M, Sauter G, Monni O, Elkahloun A, et al. (2002). Impact of
DNA amplification on gene expression patterns in breast cancer. Cancer Res 62,
6240–6245.
[23] Järvinen A-K, Autio R, Kilpinen S, Saarela M, Leivo I, Grénman R, Mäkitie
AA, and Monni O (2008). High-resolution copy number and gene expression
microarray analyses of head and neck squamous cell carcinoma cell lines of
tongue and larynx. Genes Chromosomes Cancer 47, 500–509.
[24] Myllykangas S, Junnila S, Kokkola A, Autio R, Scheinin I, Kiviluoto T,
Karjalainen-Lindsberg M-L, Hollmén J, Knuutila S, Puolakkainen P, et al.
(2008). Integrated gene copy number and expression microarray analysis of
gastric cancer highlights potential target genes. Int J Cancer 123, 817–825.
[25] Balsara BR, Sonoda G, du Manoir S, Siegfried JM, Gabrielson E, and Testa JR
(1997). Comparative genomic hybridization analysis detects frequent, often
high-level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in
human non-small cell lung carcinomas. Cancer Res 57, 2116–2120.
[26] Danner BC, Hellms T, Jung K, Gunawan B, Didilis V, Füzesi L, and
Schöndube FA (2011). Prognostic value of chromosomal imbalances in
squamous cell carcinoma and adenocarcinoma of the lung. Ann Thorac Surg
92, 1038–1043.
[27] Boelens MC, Kok K, van der Vlies P, van der Vries G, Sietsma H, Timens W,
Postma DS, Groen HJM, and van den Berg A (2009). Genomic aberrations in
squamous cell lung carcinoma related to lymph node or distant metastasis. Lung
Cancer 66, 372–378.
[28] Belvedere O, Berri S, Chalkley R, Conway C, Barbone F, Pisa F, Maclennan K,
Daly C, Alsop M, Morgan J, et al. (2011). A computational index derived from
whole-genome copy number analysis is a novel tool for prognosis in early stage
lung squamous cell carcinoma. Genomics 99, 18–24.
[29] Kim T-M, Yim S-H, Lee J-S, Kwon M-S, Ryu J-W, Kang H-M, Fiegler H,
Carter NP, and Chung Y-J (2005). Genome-wide screening of genomic al-
terations and their clinicopathologic implications in non–small cell lung cancers.
Clin Cancer Res 11, 8235–8242.
[30] Yan W, Song L, Liang Q, and Fang Y (2005). Progression analysis of lung
squamous cell carcinomas by comparative genomic hybridization. Tumor Biol
26, 158–164.
[31] McCaughan F, Pole JCM, Bankier AT, Konfortov BA, Carroll B, Falzon M,
Rabbitts TH, George PJ, Dear PH, and Rabbitts PH (2010). Progressive 3q
amplification consistently targets SOX2 in preinvasive squamous lung cancer.
Am J Respir Crit Care Med 182, 83–91.
[32] Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY,
Wardwell L, Tamayo P, Gat-Viks I, et al. (2009). SOX2 is an amplified lineage-
survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet
41, 1238–1242.
[33] Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembel D, Martinet N,
Thibault C, Huelsken J, Brambilla E, et al. (2010). SOX2 is an oncogene
activated by recurrent 3q26.3 amplifications in human lung squamous cell
carcinomas. PLoS One 5, e8960.
[34] MeehanM, Parthasarathi L, Moran N, Jefferies C, Foley N, Lazzari E, Murphy D,
Ryan J, Ortiz B, Fabius AWM, et al. (2012). Protein tyrosine phosphatase receptor
delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase
a oncogene. Mol Cancer 11, 6.
[35] Giefing M, Zemke N, Brauze D, Kostrzewska-Poczekaj M, Luczak M,
Szaumkessel M, Pelinska K, Kiwerska K, Tönnies H, Grenman R, et al. (2011).
High resolution ArrayCGH and expression profiling identifies PTPRD and
PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell
carcinoma. Genes Chromosomes Cancer 50, 154–166.
[36] Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, Sanchez-
Cespedes M, Minna JD, and Yokota J (2010). A catalog of genes homozygously
deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor
gene. Genes Chromosomes Cancer 49, 342–352.
[37] Sclafani R and Schauer I (1996). Cell cycle control and cancer: lessons from lung
cancer. J Investig Dermatol Symp Proc 1, 5.
[38] Wiest JS, Franklin WA, Otstot JT, Forbey K, Varella-Garcia M, Rao K,
Drabkin H, Gemmill R, Ahrent S, Sidransky D, et al. (1997). Identification
of a novel region of homozygous deletion on chromosome 9p in squamous cell
carcinoma of the lung: the location of a putative tumor suppressor gene. Cancer
Res 57, 1–6.
[39] Panani AD, Maliaga K, Babanaraki A, and Bellenis ION (2009). Numerical
abnormalities of chromosome 9 and p16CDKN2A gene deletion detected by FISH
in non-small cell lung cancer. Anticancer Res 29, 4483–4487.
[40] Kraunz KS, Nelson HH, Lemos M, Godleski JJ, Wiencke JK, and Kelsey KT
(2006). Homozygous deletion of p16INK4a and tobacco carcinogen exposure in
nonsmall cell lung cancer. Int J Cancer 118, 1364–1369.
[41] Elkiran E, Mar N, Aygen B, Gursu F, Karaoglu A, and Koca S (2007). Serum
paraoxonase and arylesterase activities in patients with lung cancer in a Turkish
population. BMC Cancer 7, 48.
[42] Tymms MJ, Ng AY, Thomas RS, Schutte BC, Zhou J, Eyre HJ, Sutherland
GR, Seth A, Rosenberg M, Papas T, et al. (1997). A novel epithelial-expressed
ETS gene, ELF3: human and murine cDNA sequences, murine genomic
organization, human mapping to 1q32.2 and expression in tissues and cancer.
Oncogene 15, 2449–2462.
[43] Oliver JR, Kushwah R, Wu J, Pan J, Cutz E, Yeger H, Waddell TK, and Hu J
(2011). Elf3 plays a role in regulating bronchiolar epithelial repair kinetics
following Clara cell-specific injury. Lab Invest 91, 1514–1529.
[44] Hayashi S, Kumai T, Matsuda Y, Aoki N, Sato K, Kimura S, Kitada M,
Tateno M, Celis E, and Kobayashi H (2011). Six-transmembrane epithelial
antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic
targets for lung cancer. J Transl Med 9, 191.
[45] Watanabe T, Miura T, Degawa Y, Fujita Y, Inoue M, Kawaguchi M, and
Furihata C (2010). Comparison of lung cancer cell lines representing four
histopathological subtypes with gene expression profiling using quantitative
real-time PCR. Cancer Cell Int 10, 2.
[46] Bauer M, Aust G, and Schumacher U (2004). Different transcriptional expression
of KIAA1324 and its splicing variants in human carcinoma cell lines with dif-
ferent metastatic capacity. Oncology Rep 11, 3.
[47] Deng L, Feng J, and Broaddus RR (2010). The novel estrogen-induced gene
EIG121 regulates autophagy and promotes cell survival under stress. Cell Death
Dis 1, e32.
[48] Dompe N, Rivers CS, Li L, Cordes S, Schwickart M, Punnoose EA, Amler L,
Seshagiri S, Tang J, Modrusan Z, et al. (2011). A whole-genome RNAi screen
identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis.
Proc Natl Acad Sci USA 108, E943–E951.
[49] Subramani D and Alahari S (2010). Integrin-mediated function of Rab GTPases
in cancer progression. Mol Cancer 9, 312.
[50] Dranoff G (2004). Cytokines in cancer pathogenesis and cancer therapy. Nat
Rev Cancer 4, 11–22.
[51] Fukuyama T, Ichiki Y, Yamada S, Shigematsu Y, Baba T, Nagata Y, Mizukami M,
Sugaya M, Takenoyama M, Hanagiri T, et al. (2007). Cytokine production of
lung cancer cell lines: correlation between their production and the inflammatory/
immunological responses both in vivo and in vitro. Cancer Sci 98, 1048–1054.
[52] Qi C, Zhu YT, Hu L, and Zhu Y-J (2009). Identification of Fat4 as a candidate
tumor suppressor gene in breast cancers. Int J Cancer 124, 793–798.
[53] Chen S, Lin C, Chen Y, Fang H, Cheng C, Chang C, Chen R, Tai H, Lee C,
Chou M, et al. (2006). Aberrant promoter methylation of EDNRB in lung cancer
in Taiwan. Oncology Rep 15, 5.
[54] Ladanyi M and Pao W (2008). Lung adenocarcinoma: guiding EGFR-targeted
therapy and beyond. Mod Pathol 21, S16–S22.
Neoplasia Vol. 14, No. 11, 2012 Transcriptional Consequences of Lung SCC Variants Stead et al. 1085
[55] Lockwood WW, Wilson IM, Coe BP, Chari R, Pikor LA, Thu KL, Solis LM,
Nunez MI, Behrens C, Yee J, et al. (2012). Divergent genomic and epigenomic
landscapes of lung cancer subtypes underscore the selection of different onco-
genic pathways during tumor development. PLoS One 7, e37775.
[56] Hanahan D and Weinberg RA (2000). The hallmarks of cancer. Cell 100,
57–70.
[57] Costa FF (2005). Non-coding RNAs: new players in eukaryotic biology. Gene
357, 83–94.
[58] Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai M-C,
Hung T, Argani P, Rinn JL, et al. (2010). Long non-coding RNA HOTAIR re-
programs chromatin state to promote cancer metastasis. Nature 464, 1071–1076.
[59] Marshall L and White RJ (2008). Non-coding RNA production by RNA poly-
merase III is implicated in cancer. Nat Rev Cancer 8, 911–914.
[60] Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M,
Benjamin H, Shabes N, Tabak S, Levy A, et al. (2008). MicroRNAs accurately
identify cancer tissue origin. Nat Biotechnol 26, 462–469.
[61] Mattick J (2007). A new paradigm for developmental biology. J Exp Biol 210,
1526–1547.
[62] Guttman M, Amit I, Garber M, French C, Lin M, Feldser D, Huarte M,
Zuk O, Carey B, and Cassady J (2009). Chromatin signature reveals over a
thousand highly conserved large non-coding RNAs in mammals. Nature 458,
223–227.
[63] Liao J, Yu L, Mei Y, Guarnera M, Shen J, Li R, Liu Z, and Jiang F (2010).
Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer.
Mol Cancer 9, 198.
[64] Ravi A, Gurtan AM, Kumar MS, Bhutkar A, Chin C, Lu V, Lees JA, Jacks T,
and Sharp PA (2012). Proliferation and tumorigenesis of a murine sarcoma cell
line in the absence of DICER1. Cancer Cell 21, 848–855.
[65] Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, and
Jacks T (2008). Suppression of non-small cell lung tumor development by the
let-7 microRNA family. Proc Natl Acad Sci USA 105, 3903–3908.
[66] Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H,
Harano T, Yatabe Y, Nagino M, Nimura Y, et al. (2004). Reduced expression
of the let-7 microRNAs in human lung cancers in association with shortened
postoperative survival. Cancer Res 64, 3753–3756.
[67] Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M,
Goldstein AM, Linnoila I, Marincola FM, et al. (2010). MicroRNA expression
differentiates histology and predicts survival of lung cancer. Clin Cancer Res 16,
430–441.
[68] Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, and Westra WH
(2010). Accurate classification of non–small cell lung carcinoma using a novel
microRNA-based approach. Clin Cancer Res 16, 610–619.
[69] Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T,
Sakamoto H, Tsuta K, Furuta K, Shimada Y, et al. (2012). KIF5B-RET fusions
in lung adenocarcinoma. Nat Med 18, 375–377.
[70] Yin D-T, Wang L, Sun J, Yin F, Yan Q, Shen R-L, Gao J-X, and He G (2010).
Homozygous deletion but not mutation of exons 5 and 8 of the fragile histidine
triad (FHIT) gene is associated with features of differentiated thyroid carcinoma.
Ann Clin Lab Sci 40, 267–272.
[71] Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z,
Mori M, McCue P, Druck T, et al. (1996). The FHIT gene, spanning the
chromosome 3p14.2 fragile site and renal carcinoma–associated t(3;8) break-
point, is abnormal in digestive tract cancers. Cell 84, 587–597.
[72] Mandai M, Konishi I, Kuroda H, Nanbu K, Matsushita K, Yura Y, Hamid AA,
and Mori T (1998). Expression of abnormal transcripts of the FHIT (Fragile
Histidine Triad) gene in ovarian carcinoma. Eur J Cancer 34, 745–749.
[73] Prakash T, Sharma VK, Adati N, Ozawa R, Kumar N, Nishida Y, Fujikake T,
Takeda T, and Taylor TD (2010). Expression of conjoined genes: another
mechanism for gene regulation in eukaryotes. PLoS One 5, e13284.
[74] Kim R, Kim A, Choi S-H, Kim D-S, Nam S-H, Kim D-W, Kim D-W, Kang A,
Kim M-Y, Park K-H, et al. (2012). Novel mechanism of conjoined gene forma-
tion in the human genome. Funct Integr Genomics 12, 45–61.
[75] Rackham O, Davies SMK, Shearwood A-MJ, Hamilton KL, Whelan J, and
Filipovska A (2009). Pentatricopeptide repeat domain protein 1 lowers the levels
of mitochondrial leucine tRNAs in cells. Nucleic Acids Res 37, 5859–5867.
[76] Lemarie A and Grimm S (2011). Mitochondrial respiratory chain complexes:
apoptosis sensors mutated in cancer? Oncogene 30, 3985–4003.
[77] Faghihi MA and Wahlestedt C (2009). Regulatory roles of natural antisense
transcripts. Nat Rev Mol Cell Biol 10, 637–643.
[78] Hu Q, Lu J-F, Luo R, Sen S, and Maity SN (2006). Inhibition of CBF/NF-Y
mediated transcription activation arrests cells at G2/M phase and suppresses
expression of genes activated at G2/M phase of the cell cycle. Nucleic Acids
Res 34, 6272–6285.
[79] Imbriano C, Gnesutta N, and Mantovani R (2012). The NF-Y/p53 liaison: well
beyond repression. Biochim Biophys Acta 1825, 131–139.
[80] Sasajima Y, Tanaka H, Miyake S, and Yuasa Y (2005). A novel EID family
member, EID-3, inhibits differentiation and forms a homodimer or heterodimer
with EID-2. Biochem Biophys Res Commun 333, 969–975.
[81] Chishti AH, Kim AC, Marfatia SM, Lutchman M, Hanspal M, Jindal H, Liu
S-C, Low PS, Rouleau GA, Mohandas N, et al. (1998). The FERM domain:
a unique module involved in the linkage of cytoplasmic proteins to the mem-
brane. Trends Biochem Sci 23, 281–282.
[82] Haitina T, Lindblom J, Renström T, and Fredriksson R (2006). Fourteen novel
human members of mitochondrial solute carrier family 25 (SLC25) widely
expressed in the central nervous system. Genomics 88, 779–790.
[83] Garnis C, Lockwood WW, Vucic E, Ge Y, Girard L, Minna JD, Gazdar AF,
Lam S, MacAulay C, and Lam WL (2006). High resolution analysis of non-
small cell lung cancer cell lines by whole genome tiling path array CGH. Int
J Cancer 118, 1556–1564.
[84] Qian J and Massion P (2008). Role of chromosome 3q amplification in lung
cancer. J Thorac Oncol 3, 4.
[85] Zabarovsky ER, Lerman MI, and Minna JD (2002). Tumor suppressor genes
on chromosome 3p involved in the pathogenesis of lung and other cancers.
Oncogene 21, 21.
[86] Kang J, Lee SY, Lee SY, Kim YJ, Park JY, Kwon SJ, Na MJ, Lee EJ, Jeon HS,
and Son JW (2012). MicroRNA-99b acts as a tumor suppressor in non-small cell
lung cancer by directly targeting fibroblast growth factor receptor 3. Exp Ther
Med 3, 149–153.
[87] Visone R and Croce CM (2009). MiRNAs and cancer. Am J Pathol 174,
1131–1138.
[88] Keller A, Backes C, Leidinger P, Kefer N, Boisguerin V, Barbacioru C, Vogel B,
Matzas M, Huwer H, Katus HA, et al. (2011). Next-generation sequencing
identifies novel microRNAs in peripheral blood of lung cancer patients. Mol
BioSyst 7, 3187–3199.
[89] Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, Visone R,
Iorio M, Roldo C, Ferracin M, et al. (2006). A microRNA expression signature
of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103,
2257–2261.
[90] The Cancer Genome Atlas Network (2012). Comprehensive genomic charac-
terization of squamous cell lung cancers. Nature 489, 519–525.
[91] Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E,
Cho J, Suh J, Capelletti M, Sivachenko A, et al. (2012). Mapping the hall-
marks of lung adenocarcinoma with massively parallel sequencing. Cell 150,
1107–1120.
1086 Transcriptional Consequences of Lung SCC Variants Stead et al. Neoplasia Vol. 14, No. 11, 2012
Figure W1. The karyogram for LIMM-NBE1. Estimated ploidy for LIMM-NBE1: a normal bronchial epithelium cell line that was created
in-house by h-TERT transformation. The red dots show windows in which a copy number gain was inferred (normalized against pooled
samples of normal tissue), whereas blue indicates regions of loss. The thick black line is the predicted ploidy.
Figure W2. The effects of copy number on expression for different types of transcript or across 50-kb windows genome-wide. Boxplots
showing the range of expression values in the tumor (top) or fold change in expression between normal and tumor (bottom) for different
copy number, split by functional transcript class. Expression is quantified as RPKM. Ploidy is denoted as copy numbers 1 to 6 (CN_1–CN_6).
SCC: squamous cell carcinoma.
